The KANK2 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population created by disrupting the KANK2 gene in the SK-HEP-1 human hepatocellular carcinoma cell line. This heterogeneous pool of gene-edited cells serves as a loss-of-function model to investigate the biological roles of KANK2, a scaffold protein implicated in focal adhesion dynamics and actin cytoskeleton organization. The polyclonal nature of this product provides a genetically diverse population, enabling robust assessment of KANK2-dependent phenotypes without clonal selection bias.
The SK-HEP-1 host cell line is an epithelial cell line originally established from ascites of a patient with liver adenocarcinoma. As a widely used hepatocellular carcinoma model, SK-HEP-1 cells are valuable for hepatic metabolism investigations and for dissecting molecular mechanisms underlying liver cancer progression. These cells exhibit characteristic epithelial morphology and retain key signaling pathways relevant to hepatic function and oncogenic transformation. The combination of KANK2 gene disruption with the SK-HEP-1 background offers a physiologically pertinent system for examining how KANK2 modulates cell behavior in a liver cancer context.
KANK2 functions as a molecular adapter at focal adhesions, where it binds talin-1 and talin-2, inhibiting talin-mediated actin bundling and promoting focal adhesion disassembly. This activity facilitates cell migration and cytoskeletal reorganization. KANK2 is regulated by integrin receptors, RhoA, Rac1, and mechanical stress, and it operates within integrin signaling and Rho GTPase pathways. It interacts with 14-3-3 proteins, integrin beta subunits, and actin filaments, and its downstream effects include actin cytoskeleton remodeling and focal adhesion turnover. By dissociating talin from actin, KANK2 influences cell adhesion strength and motility, linking extracellular matrix cues to dynamic cytoskeletal responses.
In the context of hepatocellular carcinoma, KANK2 has been implicated in cancer cell metastasis, with alterations in focal adhesion dynamics contributing to invasive behavior. The SK-HEP-1 liver adenocarcinoma model, combined with KANK2 knockout, provides a relevant platform to study how loss of KANK2 function affects migration, invasion, and adhesion in a tumorigenic hepatic environment. This model is also pertinent to nephrotic syndrome type 16, a disease linked to KANK2 mutations, but its primary utility lies in dissecting KANK2??s role in cytoskeletal regulation. Researchers can use these polyclonal knockout cells to compare wild-type and KANK2-deficient populations, revealing mechanisms by which KANK2 suppresses or promotes metastatic potential in liver cancer.
Typical research applications include cell migration and invasion assays using wound healing and Transwell systems, immunofluorescence staining of actin and paxillin to assess focal adhesion morphology, and Western blot analysis of KANK2 and talin expression. Integrin activation assays and 3D spheroid invasion studies further enable detailed characterization of KANK2-dependent signaling. For further information, please contact Ascent Research.
